| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Korea | 3.7 | 3.4 | | | | | | |
| China | 4.8 | 0.9 | | | | | | |
| Dermatology Recurring Procedures | | | | 23.7 | 21.1 | 23.0 | 23.5 | 14.6 |
| Dermatology Procedures Equipment | | | | 7.9 | 8.8 | 8.8 | 7.1 | 3.6 |
| Other | 27.7 | 25.7 | | | | 0.0 | 0.1 | 0.3 |
| Total revenues | 36.2 | 30.0 | 23.1 | 31.6 | 29.9 | 31.8 | 30.7 | 18.5 |
| Revenue growth [+] | 20.6% | 29.8% | -26.9% | 5.8% | -6.0% | 3.4% | 66.0% | 1921.3% |
| Korea | 10.8% | | | | | | | |
| China | 410.3% | | | | | | | |
| Dermatology Recurring Procedures | | | | 12.6% | -8.3% | -2.4% | 60.8% | |
| Dermatology Procedures Equipment | | | | -10.6% | 0.1% | 24.4% | 96.7% | |
| Dermatology Imaging | | | | | | -87.3% | -53.5% | -68.5% |
| Cost of goods sold | 14.4 | 10.1 | 9.0 | 11.3 | 12.7 | 13.0 | 12.6 | 13.7 |
| Gross profit | 21.8 | 19.9 | 14.1 | 20.3 | 17.1 | 18.8 | 18.1 | 4.8 |
| Gross margin | 60.2% | 66.2% | 61.2% | 64.2% | 57.3% | 59.1% | 58.8% | 25.8% |
| Selling, general and administrative [+] | 25.4 | 22.8 | 16.9 | 22.3 | 19.4 | 18.9 | 19.7 | 19.2 |
| Sales and marketing | 15.3 | 13.1 | 9.0 | 12.0 | 10.6 | 11.2 | 12.1 | 9.2 |
| General and administrative | 10.1 | 9.7 | 7.9 | 10.3 | 8.8 | 7.6 | 7.6 | 10.0 |
| Other selling, general and administrative | | | | | | | | |
| Research and development | 1.0 | 1.4 | 1.3 | 1.0 | 1.1 | 1.7 | 1.9 | 2.0 |
| EBITDA [+] | 0.6 | -0.7 | -0.5 | 1.5 | 2.0 | 4.5 | 2.8 | -12.4 |
| EBITDA growth | -196.7% | 35.6% | -132.9% | -26.9% | -55.0% | 63.8% | -122.3% | -16.2% |
| EBITDA margin | 1.8% | -2.2% | -2.1% | 4.7% | 6.8% | 14.3% | 9.0% | -67.2% |
| Depreciation | 2.4 | 2.1 | 2.0 | 2.7 | 3.6 | 4.3 | 4.6 | 4.1 |
| EBITA | -1.7 | -2.8 | -2.5 | -1.2 | -1.5 | 0.2 | -1.8 | -16.5 |
| EBITA margin | -4.8% | -9.3% | -10.7% | -3.8% | -5.1% | 0.6% | -5.8% | -89.1% |
| Amortization of intangibles | 2.9 | 1.6 | 1.6 | 1.8 | 1.8 | 2.0 | 1.8 | |
| EBIT [+] | -4.6 | -4.4 | -4.1 | -3.0 | -3.4 | -1.8 | -3.6 | -16.5 |
| EBIT growth | 5.6% | 8.0% | 35.4% | -10.3% | 86.5% | -50.0% | -78.2% | -0.9% |
| EBIT margin | -12.9% | -14.7% | -17.7% | -9.5% | -11.2% | -5.7% | -11.7% | -89.1% |
| Interest expense, net [+] | 0.8 | 0.3 | 0.1 | 0.5 | 1.1 | 3.2 | 4.9 | 10.2 |
| Interest expense | 0.9 | 0.3 | 0.2 | 0.5 | 1.1 | 3.2 | 4.9 | 10.2 |
| Interest income | 0.1 | 0.0 | 0.2 | | | | | |
| Other income (expense), net [+] | | 2.0 | | -0.4 | 0.2 | -16.4 | 5.4 | 1.8 |
| Gain (loss) on debt retirement | | | | -0.4 | | -20.2 | | |
| Change in fair value of warrants | | | | | | 0.6 | 5.4 | 1.8 |
| Other | | | | | 0.2 | 0.0 | 0.0 | 0.0 |
| Pre-tax income | -5.5 | -2.7 | -4.1 | -3.9 | -4.3 | -21.4 | -3.1 | -24.8 |
| Income taxes | 0.1 | 0.0 | 0.3 | -0.1 | -0.3 | 0.1 | 0.3 | 0.1 |
| Tax rate | | | | 3.8% | 6.1% | | | |
| Net income | -5.5 | -2.7 | -4.4 | -3.8 | -2.9 | -8.9 | -3.3 | -27.9 |
| Net margin | -15.3% | -9.0% | -19.1% | -12.0% | -9.7% | -27.9% | -10.9% | -150.9% |
| |
| Basic EPS [+] | ($0.16) | ($0.08) | ($0.13) | ($0.12) | ($0.15) | ($3.26) | ($1.57) | ($3.27) |
| Growth | 101.2% | -39.5% | 10.8% | -20.2% | -95.4% | 107.2% | -51.9% | 8.0% |
| Diluted EPS [+] | ($0.16) | ($0.08) | ($0.13) | ($0.12) | ($0.15) | ($3.26) | ($1.44) | ($3.27) |
| Growth | 101.2% | -39.5% | 10.8% | -20.2% | -95.4% | 126.5% | -55.9% | 8.0% |
| |
| Shares outstanding (basic) [+] | 34.7 | 34.1 | 33.6 | 32.0 | 19.6 | 2.7 | 2.1 | 8.5 |
| Growth | 1.9% | 1.3% | 5.1% | 63.2% | 621.8% | 28.1% | -75.2% | 61.2% |
| Shares outstanding (diluted) [+] | 34.7 | 34.1 | 33.6 | 32.0 | 19.6 | 2.7 | 2.3 | 8.5 |
| Growth | 1.9% | 1.3% | 5.1% | 63.2% | 621.8% | 17.2% | -72.9% | 61.2% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |